Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.07
FMS's Cash to Debt is ranked higher than
56% of the 246 Companies
in the Global Medical Care industry.

( Industry Median: 0.19 vs. FMS: 0.07 )
FMS' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.07

Equity to Asset 0.39
FMS's Equity to Asset is ranked higher than
65% of the 246 Companies
in the Global Medical Care industry.

( Industry Median: 0.48 vs. FMS: 0.39 )
FMS' s 10-Year Equity to Asset Range
Min: 0.34   Max: 0.5
Current: 0.39

0.34
0.5
Interest Coverage 5.04
FMS's Interest Coverage is ranked higher than
67% of the 170 Companies
in the Global Medical Care industry.

( Industry Median: 5.75 vs. FMS: 5.04 )
FMS' s 10-Year Interest Coverage Range
Min: 1.6   Max: 9999.99
Current: 5.04

1.6
9999.99
F-Score: 7
Z-Score: 2.35
M-Score: -2.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 14.87
FMS's Operating margin (%) is ranked higher than
87% of the 248 Companies
in the Global Medical Care industry.

( Industry Median: 9.70 vs. FMS: 14.87 )
FMS' s 10-Year Operating margin (%) Range
Min: 7.8   Max: 16.51
Current: 14.87

7.8
16.51
Net-margin (%) 7.11
FMS's Net-margin (%) is ranked higher than
81% of the 248 Companies
in the Global Medical Care industry.

( Industry Median: 5.53 vs. FMS: 7.11 )
FMS' s 10-Year Net-margin (%) Range
Min: -6.47   Max: 8.6
Current: 7.11

-6.47
8.6
ROE (%) 11.51
FMS's ROE (%) is ranked higher than
80% of the 241 Companies
in the Global Medical Care industry.

( Industry Median: 9.51 vs. FMS: 11.51 )
FMS' s 10-Year ROE (%) Range
Min: -12.24   Max: 14.9
Current: 11.51

-12.24
14.9
ROA (%) 4.56
FMS's ROA (%) is ranked higher than
75% of the 248 Companies
in the Global Medical Care industry.

( Industry Median: 4.08 vs. FMS: 4.56 )
FMS' s 10-Year ROA (%) Range
Min: -4.64   Max: 6.13
Current: 4.56

-4.64
6.13
ROC (Joel Greenblatt) (%) 36.90
FMS's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 248 Companies
in the Global Medical Care industry.

( Industry Median: 19.21 vs. FMS: 36.90 )
FMS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 26.97   Max: 77.44
Current: 36.9

26.97
77.44
Revenue Growth (%) 6.10
FMS's Revenue Growth (%) is ranked higher than
72% of the 202 Companies
in the Global Medical Care industry.

( Industry Median: 7.20 vs. FMS: 6.10 )
FMS' s 10-Year Revenue Growth (%) Range
Min: -13.5   Max: 13.7
Current: 6.1

-13.5
13.7
EBITDA Growth (%) 5.10
FMS's EBITDA Growth (%) is ranked higher than
72% of the 167 Companies
in the Global Medical Care industry.

( Industry Median: 6.60 vs. FMS: 5.10 )
FMS' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 41.3
Current: 5.1

0
41.3
EPS Growth (%) 3.20
FMS's EPS Growth (%) is ranked higher than
66% of the 152 Companies
in the Global Medical Care industry.

( Industry Median: 10.90 vs. FMS: 3.20 )
FMS' s 10-Year EPS Growth (%) Range
Min: -11.1   Max: 64.1
Current: 3.2

-11.1
64.1
» FMS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

FMS Guru Trades in Q3 2013

John Keeley 40,000 sh (unchged)
Manning & Napier Advisors, Inc 280,260 sh (unchged)
Steven Cohen Sold Out
Jim Simons 105,700 sh (-9.35%)
» More
Q4 2013

FMS Guru Trades in Q4 2013

John Keeley 40,480 sh (+1.2%)
Manning & Napier Advisors, Inc 273,750 sh (-2.32%)
Jim Simons 73,100 sh (-30.84%)
» More
Q1 2014

FMS Guru Trades in Q1 2014

Manning & Napier Advisors, Inc 273,750 sh (unchged)
Jim Simons Sold Out
John Keeley 40,335 sh (-0.36%)
» More
Q2 2014

FMS Guru Trades in Q2 2014

Jim Simons 215,700 sh (New)
Manning & Napier Advisors, Inc 273,750 sh (unchged)
John Keeley 40,000 sh (-0.83%)
» More
» Details

Insider Trades

Latest Guru Trades with FMS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Keeley 2012-12-31 Add 97.4%0.02%$32.83 - $38.93 $ 34.92-1%40000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Fresenius Medical Care AG & Co. KGaA

SymbolPriceYieldDescription
FMCMF67.800.00
FME3.Germany54.200.96
0EH5.UK54.001.05
FMSPR0.001.06ADR

Ratios

vs
industry
vs
history
P/E(ttm) 21.20
FMS's P/E(ttm) is ranked higher than
85% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 39.00 vs. FMS: 21.20 )
FMS' s 10-Year P/E(ttm) Range
Min: 12.89   Max: 27.06
Current: 21.2

12.89
27.06
P/B 2.40
FMS's P/B is ranked higher than
75% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 2.88 vs. FMS: 2.40 )
FMS' s 10-Year P/B Range
Min: 1.3   Max: 4.01
Current: 2.4

1.3
4.01
P/S 1.40
FMS's P/S is ranked higher than
69% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 1.49 vs. FMS: 1.40 )
FMS' s 10-Year P/S Range
Min: 0.99   Max: 1.93
Current: 1.4

0.99
1.93
PFCF 24.20
FMS's PFCF is ranked higher than
79% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 45.98 vs. FMS: 24.20 )
FMS' s 10-Year PFCF Range
Min: 10.97   Max: 54
Current: 24.2

10.97
54
EV-to-EBIT 13.90
FMS's EV-to-EBIT is ranked higher than
85% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 25.93 vs. FMS: 13.90 )
FMS' s 10-Year EV-to-EBIT Range
Min: 7.3   Max: 50.8
Current: 13.9

7.3
50.8
PEG 17.58
FMS's PEG is ranked higher than
83% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. FMS: 17.58 )
FMS' s 10-Year PEG Range
Min: 0.75   Max: 20.63
Current: 17.58

0.75
20.63
Shiller P/E 21.40
FMS's Shiller P/E is ranked higher than
91% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 228.10 vs. FMS: 21.40 )
FMS' s 10-Year Shiller P/E Range
Min: 17.38   Max: 33.57
Current: 21.4

17.38
33.57
Current Ratio 1.85
FMS's Current Ratio is ranked higher than
83% of the 248 Companies
in the Global Medical Care industry.

( Industry Median: 1.37 vs. FMS: 1.85 )
FMS' s 10-Year Current Ratio Range
Min: 0.8   Max: 1.93
Current: 1.85

0.8
1.93
Quick Ratio 1.50
FMS's Quick Ratio is ranked higher than
78% of the 248 Companies
in the Global Medical Care industry.

( Industry Median: 1.25 vs. FMS: 1.50 )
FMS' s 10-Year Quick Ratio Range
Min: 0.7   Max: 1.61
Current: 1.5

0.7
1.61

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.10
FMS's Dividend Yield is ranked higher than
55% of the 150 Companies
in the Global Medical Care industry.

( Industry Median: 1.43 vs. FMS: 1.10 )
FMS' s 10-Year Dividend Yield Range
Min: 0.86   Max: 1.94
Current: 1.1

0.86
1.94
Dividend Payout 0.21
FMS's Dividend Payout is ranked higher than
92% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. FMS: 0.21 )
FMS' s 10-Year Dividend Payout Range
Min: 0.67   Max: 1.36
Current: 0.21

0.67
1.36
Dividend growth (3y) -100.00
FMS's Dividend growth (3y) is ranked higher than
53% of the 99 Companies
in the Global Medical Care industry.

( Industry Median: 5.30 vs. FMS: -100.00 )
FMS' s 10-Year Dividend growth (3y) Range
Min: 0   Max: -5.7
Current: -100

Yield on cost (5-Year) 1.10
FMS's Yield on cost (5-Year) is ranked lower than
59% of the 155 Companies
in the Global Medical Care industry.

( Industry Median: 2.00 vs. FMS: 1.10 )
FMS' s 10-Year Yield on cost (5-Year) Range
Min: 0.86   Max: 1.94
Current: 1.1

0.86
1.94
Share Buyback Rate -0.50
FMS's Share Buyback Rate is ranked higher than
81% of the 177 Companies
in the Global Medical Care industry.

( Industry Median: -1.40 vs. FMS: -0.50 )
FMS' s 10-Year Share Buyback Rate Range
Min: 0.6   Max: -26.6
Current: -0.5

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.30
FMS's Price/DCF (Projected) is ranked higher than
81% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 2.98 vs. FMS: 1.30 )
FMS' s 10-Year Price/DCF (Projected) Range
Min: 0.97   Max: 7.23
Current: 1.3

0.97
7.23
Price/Median PS Value 0.90
FMS's Price/Median PS Value is ranked higher than
84% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 1.23 vs. FMS: 0.90 )
FMS' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 1.74
Current: 0.9

0.23
1.74
Earnings Yield (Greenblatt) 7.10
FMS's Earnings Yield (Greenblatt) is ranked higher than
81% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 5.30 vs. FMS: 7.10 )
FMS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2   Max: 13.7
Current: 7.1

2
13.7
Forward Rate of Return (Yacktman) 7.61
FMS's Forward Rate of Return (Yacktman) is ranked higher than
74% of the 212 Companies
in the Global Medical Care industry.

( Industry Median: 8.79 vs. FMS: 7.61 )
FMS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -4.2   Max: 27.5
Current: 7.61

-4.2
27.5

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, DVA, FSNUY, BDUUF, SKHCY » details
Traded in other countries:0H9X.UK, FMCMF.USA, FMEA.Germany, FME.Germany, FMEN.Germany, FME3.Germany, 0EH5.UK, FMCQF.USA, 0QJE.UK
Fresenius Medical Care AG & Co. KGaA was originally incorporated on August 5, 1996. It is a kidney dialysis company, operating in both the field of dialysis products and the field of dialysis services. The Company's dialysis business is vertically integrated, providing dialysis treatment at its own dialysis clinics and supplying these clinics with a range of products. In addition, it sells dialysis products to other dialysis service providers. It also develops and manufactures equipment, systems and disposable products, which it sells to customers in over 120 countries. It offers life-maintaining and life-saving dialysis services and products in a market which is characterized by a favorable demographic development. It provides expanded and enhanced patient services, including renal pharmaceutical products and laboratory services, to both its own clinics and those of third parties. The Company has developed disease state management methodologies, which involve the coordination of holistic patient care for ESRD patients and which are attractive to managed care payors. It provides ESRD and chronic kidney disease management programs to about 4,000 patients. The Company's clinics also provide services for home dialysis patients, the majority of whom receive peritoneal dialysis treatment. It also provides dialysis services under contract to hospitals in the U.S. on an 'as needed' basis for hospitalized ESRD patients and for patients suffering from acute kidney failure. The Company provides laboratory testing and marketing services in the U.S. through Spectra Laboratories (Spectra). Spectra provides blood, urine and other bodily fluid testing services to determine the appropriate individual dialysis therapy for a patient and to assist physicians in determining whether a dialysis patient's therapy regimen, diet and medicines remain optimal. The Company's main trademarks are the name 'Fresenius' and the 'F' logo'. The Company's competitors in the sale of hemodialysis and peritoneal dialysis products include, Baxter International Inc., Asahi Kasei Kuraray Medical Co. Ltd., Bellco S.r.l., B. Braun Melsungen AG, Nipro Corporation Ltd., Nikkiso Co., Ltd., Terumo Corporation, Kawasumi Laboratories Inc., Fuso Pharmaceuticals Industries Ltd., and Toray Industries, Inc. The Company's operations are subject to extensive governmental regulation by virtually every country in which it operates including the U.S., at the federal, state and local levels.
» More Articles for NYSE:FMS

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: FMS, SNOW, KMDA, LAYN Jun 16 2014 
Weekly 52-Week Highs Highlight: MMP, AZO, BEAM, FMS Jan 26 2014 
comment on FMS May 01 2013 
Better Know a Company: Fresenius Medical Care (FMS) Apr 23 2013 
Solid company. Opti Mar 26 2013 
39.64 Mar 18 2013 
comment on FMS Mar 17 2013 
Warren Buffett Becomes Largest Owner of DaVita Mar 04 2013 
Warren Buffett’s Holding of DaVita Grows as Company Expands Jan 17 2013 
Buffett’s Berkshire Hathaway Buys Even More DaVita Shares Nov 29 2012 

More From Other Websites
American Association of Kidney Patients Joins Fresenius Medical Care in Advocating for Vaccinations... Sep 30 2014
Celebrity Chef Aaron McCargo Jr. and Fresenius Medical Care Offer Delicious Football-Season Recipes... Sep 17 2014
2 Solid Picks for a Weak Euro Sep 15 2014
Celebrity Chef to Share Cooking Tips for Restricted Diets At American Association of Kidney Patients... Sep 08 2014
Fresenius Medical Care Introduces New ‘Chair Yoga’ Program to Dialysis Community at Denver-Area... Aug 28 2014
Top Analyst Upgrades and Downgrades: Himax, Ocwen, RetailMeNot, Tenet and More Aug 05 2014
Wall Street Transcript Interview with Christopher J. Reading, the President and CEO of U.S. Physical... Aug 04 2014
3 Stocks Pushing The Health Services Industry Higher Jul 30 2014
3 German Stocks For Your Portfolio After The World Cup Win Jul 16 2014
3 Stocks Underperforming Today In The Health Services Industry Jul 01 2014
Chef Aaron McCargo Jr. and Fresenius Medical Care Share Kidney-Friendly Recipes to Enjoy During BBQ... Jun 30 2014
3 Stocks Boosting The Health Care Sector Higher Jun 26 2014
Fresenius Medical (FMS): Moving Average Crossover Alert Jun 10 2014
Fresenius Medical Care and Aetna Collaborate to Provide Coordinated Care Management for End Stage... Jun 10 2014
DaVita Touches New 52-Week High Jun 05 2014
3 Stocks Dragging The Health Services Industry Downward Jun 02 2014
NaturaLyte Class 1 Recall at Fresenius Medical May 30 2014
DaVita's Trial Of Nephros' HDF Dialysis Therapy Presents Opportunity For Both Firms May 29 2014
Fresenius Medical Care N.A says NaturaLyte recall classified as Class 1 May 21 2014
Voluntary Nationwide and Canada Recall of NaturaLyte® Liquid Bicarbonate Concentrate Due to... May 21 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK